Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Oragenics ( (OGEN) ) has issued an announcement.
Oragenics, Inc. has announced the conversion of its Series A and B Preferred Shares into common stock, simplifying its capital structure and eliminating a $2.35 million liquidation preference. This move is aimed at strengthening the company’s financial foundation and aligning with its long-term shareholder value creation strategy, while allowing a focus on advancing its innovative treatment pipeline.
More about Oragenics
Oragenics is a development-stage biotechnology company specializing in the nasal delivery of pharmaceutical medications targeting neurological conditions and infectious diseases. Their pipeline includes treatments for mild traumatic brain injury (concussion) and Niemann Pick Disease Type C, along with proprietary powder formulations and an intranasal delivery device.
YTD Price Performance: -94.13%
Average Trading Volume: 455,983
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.03M
For detailed information about OGEN stock, go to TipRanks’ Stock Analysis page.
